Loading
A phase 3 trial of gemcitabine and carboplatin in triple-negative breast cancer, run by Sun Yat-Sen University Cancer Center, now recruiting.
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer is a phase 3, randomised interventional study registered as NCT04722978 by Sun Yat-Sen University Cancer Center, with a registry enrolment figure of 228 participants, started 2021-04-20 and due to reach its primary completion in 2026-06. Interventions recorded: Gemcitabine and carboplatin plus antibiotic (moxifloxacin); Gemcitabine combined with carboplatin plus placebo. Conditions listed: Triple Negative Breast Cancer. Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Gemcitabine, Platinum agents and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin and the tag tnbc-deep-dive.
Shares Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Triple-negative breast cancer trials open today (registry snapshot and UK sites), Platinum agents, Carboplatin, Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/